公开(公告)号：EP2842940B1

公开(公告)日：2018-04-25

申请号：EP13757087.5

申请日：2013-03-06

申请人： Consejo Superior De Investigaciones Científicas (CSIC) ,  Universidad De Sevilla

发明人： KHIAR EL WAHABI, Noureddine ,  FERNÁNDEZ FERNÁNDEZ, Inmaculada ,  RECIO JIMÉNEZ, Rocío

IPC分类号： C07C331/20 ,  A61K31/26

CPC分类号： C07C331/20 ,  A61K31/26 ,  A61K31/795 ,  A61K45/06

摘要： The present invention relates to a new series of compounds having general formula (I) and the optical isomer or enantiomer forms thereof, which belong to the family of sulforaphane derivatives. The invention also relates to the production method thereof. The invention further relates to the multiple medical (pharmaceutical, homeopathic and phytotherapeutic), food, cosmetic and dietary uses of said series of compounds, especially the use thereof in the prevention and/or treatment of diseases and any type of illness or damage associated with an oxidative process or which, although not involved in said process, are mediated by the Nrf2 transcription factor, such as, for example, cancer. The compounds can be used alone or, alternatively, encapsulated in cyclodextrins.

公开(公告)号：EP3166602A4

公开(公告)日：2018-03-07

申请号：EP15819066

申请日：2015-07-08

申请人： MCCORD DARLENE E

发明人： MCCORD DARLENE E ,  KARAGIANNIS THOMAS

IPC分类号： A61K31/26 ,  A61K31/10 ,  A61P11/00 ,  A61P29/00 ,  A61P29/02

CPC分类号： A61K31/26 ,  A61K31/05 ,  A61K31/198 ,  A61K31/7048 ,  A61K45/06 ,  A61P11/00 ,  A61P29/00 ,  C07C331/20 ,  A61K2300/00

摘要： Compositions comprising LSF compositions and treatment regiments comprising administration of LSF containing compositions are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, including diseases associated with inflammation and/or oxidative stress, are provided. Various methods for use of the LSF compositions for inhibition of histone deacetylases (HDACs) in various cells, tissues, and/or conditions are also provided.

公开(公告)号：EP3075384A4

公开(公告)日：2017-08-16

申请号：EP14847844

申请日：2014-09-29

申请人： SUNSTAR INC

发明人： SONO YOUKO ,  SUWA MAKOTO ,  MATSUMOTO MOTONOBU

IPC分类号： A61K31/7048 ,  A61K31/05 ,  A61K31/145 ,  A61K31/26 ,  A61K36/18 ,  A61K36/31 ,  A61K36/63 ,  A61P3/04

CPC分类号： A61K31/7048 ,  A23G4/06 ,  A23G4/068 ,  A23G4/12 ,  A23L2/52 ,  A23L33/10 ,  A23L33/105 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/2054 ,  A61K9/4866 ,  A61K31/05 ,  A61K31/26 ,  A61K31/275 ,  A61K36/31 ,  A61K36/63 ,  A61K36/76 ,  A61K2300/00

摘要： An object of the present invention is to provide an obesity-suppressing composition that suppresses fat accumulation in adipocytes and that has an effect of suppressing body weight gain. The present invention provides an obesity-suppressing composition comprising the following components (A) and (B): (A) at least one member selected from the group consisting of oleuropein and hydroxytyrosol; (B) at least one member selected from the group consisting of sulforaphane compounds and willow extract.

摘要翻译： 本发明的目的在于提供抑制脂肪细胞内的脂肪蓄积，并具有抑制体重增加的效果的肥胖抑制组合物。 本发明提供一种肥胖抑制用组合物，其含有下述成分（A）和（B）：（A）选自橄榄苦苷和羟基酪醇中的至少一种; （B）选自萝卜硫烷化合物和柳树提取物中的至少一种。

公开(公告)号：EP3169332A1

公开(公告)日：2017-05-24

申请号：EP15716052.4

申请日：2015-04-14

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften

发明人： BRÜNING, Jens ,  STECULORUM, Sophie

IPC分类号： A61K31/7072 ,  A61K45/00 ,  A61K31/26 ,  A61K31/155 ,  A61P3/04 ,  G01N33/00 ,  A61P3/10 ,  A61P3/00

CPC分类号： A61K31/7072 ,  A61K31/155 ,  A61K31/26 ,  G01N2333/726 ,  G01N2500/04 ,  G01N2800/042

摘要： The present invention is related to compound capable of regulating the activity of P2Y purinoceptor 6 signaling pathway, especially to compounds for inhibition of P2Y purinoceptor 6 polypeptide or inactivation, degradation, downregulation or intercalation of a nucleic acid encoding P2Y purinoceptor 6 or downregulation of P2Y purinoceptor 6 signaling pathway for the treatment of diseases related to energy balance as well as carbohydrate metabolism and homeostasis, preferably glucose metabolism and homeostasis. The present is also related to compounds for activation of P2Y purinoceptor 6 polypeptide or upregulation or modification for advanced transcriptional activity of a nucleic acid encoding P2Y purinoceptor 6, upregulation of P2Y purinoceptor 6 signaling pathway for gaining weight or for the treatment of diseases related to energy balance and carbohydrate metabolism and homeostasis. The invention is further related to methods of identifying said compounds suitable for the treatment of diseases related to energy balance and carbohydrate metabolism and homeostasis. The invention is further related to methods of treatment and diagnosis of diseases related to energy balance and carbohydrate metabolism and homeostasis and associated complications.

摘要翻译： 本发明涉及能够调节P2Y嘌呤受体6信号传导途径活性的化合物，尤其涉及用于抑制P2Y嘌呤受体6多肽的化合物或编码P2Y嘌呤受体6的核酸的失活，降解，下调或插入或P2Y嘌呤受体的下调 6信号传导途径用于治疗与能量平衡有关的疾病以及碳水化合物代谢和体内平衡，优选葡萄糖代谢和体内平衡。 本发明还涉及用于激活P2Y嘌呤受体6多肽或上调或修饰用于编码P2Y嘌呤受体6的核酸的高级转录活性，用于获得体重的P2Y嘌呤受体6信号传导途径的上调或用于治疗与能量有关的疾病的化合物 平衡和碳水化合物代谢和体内平衡。 本发明进一步涉及鉴定适合于治疗与能量平衡和碳水化合物代谢和体内平衡有关的疾病的所述化合物的方法。 本发明还涉及治疗和诊断与能量平衡和碳水化合物代谢以及动态平衡和相关并发症有关的疾病的方法。

公开(公告)号：EP3017814A4

公开(公告)日：2017-01-04

申请号：EP14820387

申请日：2014-07-03

申请人： MITSUBISHI-KAGAKU FOODS CORP ,  INCORPORATED NAT UNIV IWATE UNIV

发明人： OKADA KEIJI ,  SEKIYAMA YASUSHI

IPC分类号： A61K31/26 ,  A61P17/00 ,  A61P31/04

CPC分类号： A61K31/26 ,  A61K9/0017

摘要： Provided is a novel method for preventing and/or treating hairy wart disease which is a hoof and leg disease of ungulates. The method is carried out by administering an isothiocyanic acid ester such as allyl isothiocyanate to a hoof of an ungulate. Examples of ungulates targeted for application of the present invention include cows such as dairy cows as well as sheep, pigs and horses.

摘要翻译： 提供一种预防和/或治疗作为有蹄类动物的蹄状腿疾病的毛疣病的新方法。 该方法通过将异硫氰酸酯如异硫氰酸烯丙酯施用于有蹄类动物的蹄来进行。 用于本发明应用的有蹄类动物的实例包括牛，如奶牛，以及绵羊，猪和马。

公开(公告)号：EP3034076A4

公开(公告)日：2016-10-19

申请号：EP14836229

申请日：2014-08-13

申请人： JC WUXI COMPANY INC

发明人： CHENG JINGCAI ,  ZHANG CHUNXIA ,  CHENG ZHIWEI

IPC分类号： A61K31/26 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/26 ,  A61K31/16 ,  A61K31/165 ,  A61K31/167 ,  A61K31/17 ,  A61K31/282 ,  A61K31/33 ,  A61K31/337 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/58 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7076 ,  A61K33/24 ,  A61K33/36 ,  A61K38/10 ,  A61K38/14 ,  A61K2300/00

摘要： The present invention relates to a combined application of isothiocyanate compounds and anti-cancer drugs, in particular to a composition, comprising: (A) a therapeutically effective amount of a first active ingredient, the first active ingredient being an isothiocyanate compound or derivative thereof; (B) a therapeutically effective amount of a second active ingredient, the second active ingredient being anti-cancer drugs effecting or influencing DNA, kinase inhibitor anti-cancer drugs or endocrine therapy hormonal anti-cancer drugs, the mass ratio of the first active ingredient and the second active ingredient being from 1:10000 to 10000:1. Also disclosed are an active ingredient composition, kit, pharmaceutical composition and uses thereof in the preparation of anti-cancer drugs. The composition, active ingredient composition and kit have excellent effect of inhibiting the growth of cancer cells.

公开(公告)号：EP2965763A9

公开(公告)日：2016-03-02

申请号：EP15166498.4

申请日：2010-04-12

申请人： Qi, Haiyan

发明人： Qi, Haiyan

IPC分类号： A61K35/74 ,  G01N33/53 ,  A61K31/436 ,  A61K31/352 ,  A61K31/047 ,  A61K31/01 ,  A61K36/45 ,  A61K36/87 ,  A61K33/06 ,  A61K31/26 ,  A61K31/105 ,  A61K31/155 ,  A61K31/4375 ,  A61K38/22 ,  A61K31/573 ,  A61K31/4709 ,  A61K31/375 ,  A61K31/355 ,  A61K31/015 ,  A61K31/385 ,  A61K31/122

CPC分类号： A61K31/436 ,  A61K8/49 ,  A61K31/01 ,  A61K31/015 ,  A61K31/05 ,  A61K31/105 ,  A61K31/122 ,  A61K31/145 ,  A61K31/155 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4045 ,  A61K31/453 ,  A61K31/4709 ,  A61K31/567 ,  A61K31/573 ,  A61K31/7004 ,  A61K31/7056 ,  A61K33/04 ,  A61K38/063 ,  A61K45/06 ,  A61Q19/08 ,  C12Q1/025 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/5044 ,  G01N33/5079 ,  G01N33/6875 ,  G01N33/6893 ,  G01N2333/39 ,  G01N2800/02 ,  Y02A90/26 ,  A61K2300/00

摘要： The present invention discloses mechanisms in the aging process and describes agents to be used for improving mitochondrial function, maintaining the cell cycle- arrested state in senescent and post mitotic cells, and thus preventing or treating age- related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders.

公开(公告)号：EP2965763A1

公开(公告)日：2016-01-13

申请号：EP15166498.4

申请日：2010-04-12

申请人： Qi, Haiyan

发明人： Qi, Haiyan

IPC分类号： A61K35/74 ,  G01N33/53 ,  A61K31/436 ,  A61K31/352 ,  A61K31/047 ,  A61K31/01 ,  A61K36/45 ,  A61K36/87 ,  A61K33/06 ,  A61K31/26 ,  A61K31/105 ,  A61K31/155 ,  A61K31/4375 ,  A61K38/22 ,  A61K31/573 ,  A61K31/4709 ,  A61K31/375 ,  A61K31/355 ,  A61K31/015 ,  A61K31/385 ,  A61K31/122

CPC分类号： A61K31/436 ,  A61K8/49 ,  A61K31/01 ,  A61K31/015 ,  A61K31/05 ,  A61K31/105 ,  A61K31/122 ,  A61K31/145 ,  A61K31/155 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4045 ,  A61K31/453 ,  A61K31/4709 ,  A61K31/567 ,  A61K31/573 ,  A61K31/7004 ,  A61K31/7056 ,  A61K33/04 ,  A61K38/063 ,  A61K45/06 ,  A61Q19/08 ,  C12Q1/025 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/5044 ,  G01N33/5079 ,  G01N33/6875 ,  G01N33/6893 ,  G01N2333/39 ,  G01N2800/02 ,  Y02A90/26 ,  A61K2300/00

摘要： The present invention discloses mechanisms in the aging process and describes agents to be used for improving mitochondrial function, maintaining the cell cycle- arrested state in senescent and post mitotic cells, and thus preventing or treating age- related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders.

摘要翻译： 本发明公开了老化过程中的机制，并描述了用于改善线粒体功能，维持衰老和有丝分裂细胞后的细胞周期阻滞状态的药剂，从而预防或治疗与加速的线粒体功能相关的年龄相关疾病或病症 损失，端粒功能障碍和/或生长停滞状态的恶化。 本发明还公开了许多化合物或组合物。 本发明进一步提供低剂量的雷帕霉素或其类似物作为模拟限制热量以防止与年龄有关的疾病或病症的用途。

公开(公告)号：EP2736520A4

公开(公告)日：2015-07-08

申请号：EP12818073

申请日：2012-07-10

申请人： WRIGLEY W M JUN CO

发明人： TIAN MINMIN ,  HANLEY BRYAN ,  DODDS MICHAEL

IPC分类号： A61K33/30 ,  A61K9/08 ,  A61K31/26 ,  A61P1/02

CPC分类号： A61K8/46 ,  A23G1/325 ,  A23G3/362 ,  A23G4/064 ,  A23K20/30 ,  A61K8/27 ,  A61K8/36 ,  A61K8/361 ,  A61K8/365 ,  A61K8/4973 ,  A61K8/676 ,  A61K9/0056 ,  A61K9/0058 ,  A61K9/2018 ,  A61K31/26 ,  A61K31/5375 ,  A61K33/30 ,  A61Q11/00 ,  A61K2300/00

摘要： Combinations of a zinc salt and an isothiocyanate are provided, and more particularly to a consumer acceptable oral composition containing such combination which is effective in the reduction of volatile sulfur compounds (VSCs).

摘要翻译： 设置有锌盐和异硫氰酸酯的组合，并且更具体地涉及一种消费者可接受的口腔组合物包含搜索所有的组合能有效挥发性硫化合物（的VSC）的还原。

公开(公告)号：EP2793876A1

公开(公告)日：2014-10-29

申请号：EP12801539.3

申请日：2012-12-10

申请人： Ares Trading S.A.

发明人： KAHRS, Bjoern Colin

IPC分类号： A61K31/225 ,  A61K31/4439 ,  A61K31/70 ,  A61K45/06 ,  A61P17/06 ,  A61P1/04 ,  A61P17/14 ,  A61P5/48 ,  A61P21/04 ,  A61K31/05 ,  A61K31/12 ,  A61K31/16 ,  A61K31/19 ,  A61K31/216 ,  A61K31/26 ,  A61K31/385 ,  A61K31/47

CPC分类号： A61K31/4439 ,  A61K9/0053 ,  A61K31/05 ,  A61K31/12 ,  A61K31/16 ,  A61K31/19 ,  A61K31/216 ,  A61K31/225 ,  A61K31/26 ,  A61K31/385 ,  A61K31/426 ,  A61K31/47 ,  Y02A50/395 ,  Y02A50/414 ,  A61K2300/00

摘要： The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

摘要翻译： 本发明涉及包含PPAR激动剂和Nrf2激活剂的药物组合物以及使用PPAR激动剂和Nrf2激活剂的组合来治疗疾病如牛皮癣，哮喘，多发性硬化，炎性肠病和关节炎的方法。